Chargement en cours...
Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
The clinical successes of chimeric antigen receptor (CAR)-T-cell therapy targeting cell surface antigens in B cell leukaemias and lymphomas has demonstrated the proof of concept that appropriately engineered T-cells have the capacity to destroy advanced cancer with long term remissions ensuing. Neve...
Enregistré dans:
| Publié dans: | Cancers (Basel) |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7463974/ https://ncbi.nlm.nih.gov/pubmed/32824734 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082326 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|